Elvitegravir

埃替格韦

Report date: 2023/09/06 20:07:03
NME

Base Information

Drug NameElvitegravir
Drug Alias Name艾维雷韦elvitegravirumelvitegravir埃替拉韦埃特雷韦 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHIV integrase inhibitors
TargetsHIV integrase
Therapy Area/IndicationsAcquired Immunodeficiency SyndromeHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2013/11/13
Country/TerritoryBelgiumCanadaUnited States +[20] 
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesGilead Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGilead Sciences International LtdGilead Sciences Inc
Active IndicationsN/A
Inactive IndicationsAcquired Immunodeficiency SyndromeHIV Infections

Other Information

ATC CodeJ05AJ02
Related LinksWikipediaDrugBankKEGG